CYP19A1 and breast cancer: Historically, HR+ BC has been mostly treated by hormone therapies (i.e., estrogen receptor blockade or aromatase inhibitors that suppress estrogen biosynthesis) and conventional chemotherapies (e.g., anthracycline and taxanes) and considered to be primarily immunoresistant [3–5].